Data management and design issues in an unmasked randomized trial of electroconvulsive therapy for relapse prevention of severe depression: The consortium for research in electroconvulsive therapy trial

Keith G. Rasmussen, Rebecca G. Knapp, Melanie M. Biggs, Glenn E. Smith, Teresa A. Rummans, Georgios Petrides, Mustafa M. Husain, M. Kevin O'Connor, Max Fink, Charles H. Kellner

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: The use of double-blind designs, normally the criterion standard of clinical trials, is impossible when comparing medication therapy to procedural therapies for depression. In the Consortium for Research in Electroconvulsive Therapy (CORE) trial, depressed patients recently remitted with electroconvulsive therapy (ECT) were randomly assigned to receive continuation therapy with either ECT or medications. The purpose of this article is to describe the design characteristics and challenges of the trial and of our method of dealing with the lack of double-blind outcome assessment. METHODS: The primary outcome measure was time to relapse of depression in the continuation phase. We developed a method to achieve partial blinding of depressive severity assessment. This consisted of videotaping the structured interviews, having the video tapes co-rated by personnel not involved in the patient's care, and a videotape-tracking maneuver so that the assessor of the videotapes could be blinded to phase and type of treatment. RESULTS: We enrolled 624 patients into the initial treatment phase of the trial. Of these, 201 met criteria for randomization into the second, continuation phase. Our videotape-tracking maneuver to reduce bias in outcome assessment worked well during the trial. CONCLUSIONS: The CORE study is the first multicenter, randomized controlled trial of continuation ECT in the relapse prevention of major depressive episodes. We successfully recruited a large number of severely depressed patients into a 6 month trial and used a method of reducing bias that might result from lack of blinding.

Original languageEnglish (US)
Pages (from-to)244-250
Number of pages7
JournalJournal of ECT
Volume23
Issue number4
DOIs
StatePublished - Dec 2007

Fingerprint

Electroconvulsive Therapy
Secondary Prevention
Videotape Recording
Depression
Research
Outcome Assessment (Health Care)
Therapeutics
Random Allocation
Patient Care
Randomized Controlled Trials
Clinical Trials
Interviews
Recurrence

Keywords

  • Clinical trial
  • Electroconvulsive therapy
  • Major depression

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Data management and design issues in an unmasked randomized trial of electroconvulsive therapy for relapse prevention of severe depression : The consortium for research in electroconvulsive therapy trial. / Rasmussen, Keith G.; Knapp, Rebecca G.; Biggs, Melanie M.; Smith, Glenn E.; Rummans, Teresa A.; Petrides, Georgios; Husain, Mustafa M.; O'Connor, M. Kevin; Fink, Max; Kellner, Charles H.

In: Journal of ECT, Vol. 23, No. 4, 12.2007, p. 244-250.

Research output: Contribution to journalArticle

Rasmussen, Keith G. ; Knapp, Rebecca G. ; Biggs, Melanie M. ; Smith, Glenn E. ; Rummans, Teresa A. ; Petrides, Georgios ; Husain, Mustafa M. ; O'Connor, M. Kevin ; Fink, Max ; Kellner, Charles H. / Data management and design issues in an unmasked randomized trial of electroconvulsive therapy for relapse prevention of severe depression : The consortium for research in electroconvulsive therapy trial. In: Journal of ECT. 2007 ; Vol. 23, No. 4. pp. 244-250.
@article{2a52d1592606497e80df9c576f6eb28d,
title = "Data management and design issues in an unmasked randomized trial of electroconvulsive therapy for relapse prevention of severe depression: The consortium for research in electroconvulsive therapy trial",
abstract = "BACKGROUND: The use of double-blind designs, normally the criterion standard of clinical trials, is impossible when comparing medication therapy to procedural therapies for depression. In the Consortium for Research in Electroconvulsive Therapy (CORE) trial, depressed patients recently remitted with electroconvulsive therapy (ECT) were randomly assigned to receive continuation therapy with either ECT or medications. The purpose of this article is to describe the design characteristics and challenges of the trial and of our method of dealing with the lack of double-blind outcome assessment. METHODS: The primary outcome measure was time to relapse of depression in the continuation phase. We developed a method to achieve partial blinding of depressive severity assessment. This consisted of videotaping the structured interviews, having the video tapes co-rated by personnel not involved in the patient's care, and a videotape-tracking maneuver so that the assessor of the videotapes could be blinded to phase and type of treatment. RESULTS: We enrolled 624 patients into the initial treatment phase of the trial. Of these, 201 met criteria for randomization into the second, continuation phase. Our videotape-tracking maneuver to reduce bias in outcome assessment worked well during the trial. CONCLUSIONS: The CORE study is the first multicenter, randomized controlled trial of continuation ECT in the relapse prevention of major depressive episodes. We successfully recruited a large number of severely depressed patients into a 6 month trial and used a method of reducing bias that might result from lack of blinding.",
keywords = "Clinical trial, Electroconvulsive therapy, Major depression",
author = "Rasmussen, {Keith G.} and Knapp, {Rebecca G.} and Biggs, {Melanie M.} and Smith, {Glenn E.} and Rummans, {Teresa A.} and Georgios Petrides and Husain, {Mustafa M.} and O'Connor, {M. Kevin} and Max Fink and Kellner, {Charles H.}",
year = "2007",
month = "12",
doi = "10.1097/yct.0b013e31814515d6",
language = "English (US)",
volume = "23",
pages = "244--250",
journal = "Journal of ECT",
issn = "1095-0680",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Data management and design issues in an unmasked randomized trial of electroconvulsive therapy for relapse prevention of severe depression

T2 - The consortium for research in electroconvulsive therapy trial

AU - Rasmussen, Keith G.

AU - Knapp, Rebecca G.

AU - Biggs, Melanie M.

AU - Smith, Glenn E.

AU - Rummans, Teresa A.

AU - Petrides, Georgios

AU - Husain, Mustafa M.

AU - O'Connor, M. Kevin

AU - Fink, Max

AU - Kellner, Charles H.

PY - 2007/12

Y1 - 2007/12

N2 - BACKGROUND: The use of double-blind designs, normally the criterion standard of clinical trials, is impossible when comparing medication therapy to procedural therapies for depression. In the Consortium for Research in Electroconvulsive Therapy (CORE) trial, depressed patients recently remitted with electroconvulsive therapy (ECT) were randomly assigned to receive continuation therapy with either ECT or medications. The purpose of this article is to describe the design characteristics and challenges of the trial and of our method of dealing with the lack of double-blind outcome assessment. METHODS: The primary outcome measure was time to relapse of depression in the continuation phase. We developed a method to achieve partial blinding of depressive severity assessment. This consisted of videotaping the structured interviews, having the video tapes co-rated by personnel not involved in the patient's care, and a videotape-tracking maneuver so that the assessor of the videotapes could be blinded to phase and type of treatment. RESULTS: We enrolled 624 patients into the initial treatment phase of the trial. Of these, 201 met criteria for randomization into the second, continuation phase. Our videotape-tracking maneuver to reduce bias in outcome assessment worked well during the trial. CONCLUSIONS: The CORE study is the first multicenter, randomized controlled trial of continuation ECT in the relapse prevention of major depressive episodes. We successfully recruited a large number of severely depressed patients into a 6 month trial and used a method of reducing bias that might result from lack of blinding.

AB - BACKGROUND: The use of double-blind designs, normally the criterion standard of clinical trials, is impossible when comparing medication therapy to procedural therapies for depression. In the Consortium for Research in Electroconvulsive Therapy (CORE) trial, depressed patients recently remitted with electroconvulsive therapy (ECT) were randomly assigned to receive continuation therapy with either ECT or medications. The purpose of this article is to describe the design characteristics and challenges of the trial and of our method of dealing with the lack of double-blind outcome assessment. METHODS: The primary outcome measure was time to relapse of depression in the continuation phase. We developed a method to achieve partial blinding of depressive severity assessment. This consisted of videotaping the structured interviews, having the video tapes co-rated by personnel not involved in the patient's care, and a videotape-tracking maneuver so that the assessor of the videotapes could be blinded to phase and type of treatment. RESULTS: We enrolled 624 patients into the initial treatment phase of the trial. Of these, 201 met criteria for randomization into the second, continuation phase. Our videotape-tracking maneuver to reduce bias in outcome assessment worked well during the trial. CONCLUSIONS: The CORE study is the first multicenter, randomized controlled trial of continuation ECT in the relapse prevention of major depressive episodes. We successfully recruited a large number of severely depressed patients into a 6 month trial and used a method of reducing bias that might result from lack of blinding.

KW - Clinical trial

KW - Electroconvulsive therapy

KW - Major depression

UR - http://www.scopus.com/inward/record.url?scp=37349042886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349042886&partnerID=8YFLogxK

U2 - 10.1097/yct.0b013e31814515d6

DO - 10.1097/yct.0b013e31814515d6

M3 - Article

C2 - 18090697

AN - SCOPUS:37349042886

VL - 23

SP - 244

EP - 250

JO - Journal of ECT

JF - Journal of ECT

SN - 1095-0680

IS - 4

ER -